| fluoxetine |
|
| CHEBI:5118 |
|
| A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
| Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class used for the treatment of major depressive disorder, anxiety, obsessive–compulsive disorder (OCD), panic disorder, premenstrual dysphoric disorder, and bulimia nervosa. It is also approved for treatment of major depressive disorder in adolescents and children 8 years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.
Common side effects include loss of appetite, nausea, diarrhea, headache, trouble sleeping, dry mouth, and sexual dysfunction. Serious side effects include serotonin syndrome, mania, seizures, an increased risk of suicidal behavior in people under 25 years old, and an increased risk of bleeding. Antidepressant discontinuation syndrome is less likely to occur with fluoxetine than with other antidepressants, but it still happens in many cases. Fluoxetine taken during pregnancy is associated with a significant increase in congenital heart defects in newborns. It has been suggested that fluoxetine therapy may be continued during breastfeeding if it was used during pregnancy or if other antidepressants were ineffective.
Fluoxetine was invented by Eli Lilly and Company in 1972 and entered medical use in 1986. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 22nd most commonly prescribed medication in the United States, with more than 24 million prescriptions.
Eli Lilly also markets fluoxetine in a fixed-dose combination with olanzapine as olanzapine/fluoxetine (Symbyax), which was approved by the US Food and Drug Administration (FDA) for the treatment of depressive episodes of bipolar I disorder in 2003 and for treatment-resistant depression in 2009. |
|
Read full article at Wikipedia
|
|
environmental contaminant
Any minor or unwanted substance introduced into the environment that can have undesired effects.
|
|
|
drug allergen
Any drug which causes the onset of an allergic reaction.
serotonin uptake inhibitor
A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
analgesic
An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
xenobiotic
A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
|
|
|
drug allergen
Any drug which causes the onset of an allergic reaction.
serotonin uptake inhibitor
A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
analgesic
An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
antidepressant
Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
|
|
View more via ChEBI Ontology
|
rac-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
|
fluoxetina
|
ChemIDplus
|
fluoxétine
|
WHO MedNet
|
|
fluoxetine
|
KEGG DRUG
|
fluoxetinum
|
ChemIDplus
|
|
(±)-N-methyl-3-phenyl-3-((α,α,α-trifluoro-p-tolyl)oxy)propylamine
|
ChemIDplus
|
|
(±)-N-methyl-γ-(4-(trifluoromethyl)phenoxy)benzenepropanamine
|
ChemIDplus
|
|
3991406
|
Reaxys Registry Number
|
Reaxys
|
|
39914106
|
Beilstein Registry Number
|
Beilstein
|
|
54910-89-3
|
CAS Registry Number
|
ChemIDplus
|
|
54910-89-3
|
CAS Registry Number
|
KEGG DRUG
|
|
2014-10-29
